Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised pilot trial of Myfortic for primary proteinuric glomerulonephritis
2009-016003-26Phase 2Terminated
- Sponsor
- University Hospitals Birmingham
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of mycophenolate sodium in Glomerulonephritis (GN), focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) (2 arms), sponsored by University Hospitals Birmingham. Primary endpoint: Sustained complete or partial remission at 24 weeks. Started Mar 2010; status: terminated.
02
Drugs
mycophenolate sodium
03
Conditions
Glomerulonephritis (GN)focal segmental glomerulosclerosis (FSGS)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2009-016003-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016003-26.